Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer

Cathryn Crockett, James Price, Mai Pham, Danya Abdulwahid, Neil Bayman, Fiona Blackhall, Layla Bostock, Raffaele Califano, Clara Chan, Joanna Coote, Laura Cove-Smith, Marie Eaton, Jacqueline Fenemore, Fabio Gomes, Margaret Harris, Emma Halkyard, Sarah Hughes, Colin Lindsay, Hilary Neal, Delyth McEnteeLaura Pemberton, Hamid Sheikh, Yvonne Summers, Paul Taylor, David Woolf, Janelle Yorke, Corinne Faivre-Finn

Research output: Contribution to journalArticlepeer-review


PURPOSE: The Christie NHS Foundation Trust launched their electronic patient-reported outcome measures (ePROMs) service in January 2019 in the routine clinical setting. The lung cancer questionnaires consist of 14 symptom items, adapted from the Common Terminology Criteria for Adverse Events (version 5.0) and the EuroQol EQ-5D-5L quality-of-life (QoL) tool. Patients with lung cancer are invited to complete questionnaires assessing their symptoms and QoL using an online platform.

METHODS: The ePROM responses and clinical, pathologic, and treatment data for patients who completed the questionnaires between January 2019 and December 2020 were extracted from electronic medical records. The symptom and QoL scores of patients who completed baseline pretreatment ePROMs and also those who completed ePROMs pre- and postpalliative lung systemic anticancer therapy (SACT) or radical thoracic radiotherapy were evaluated. Pretreatment questionnaires were analyzed according to age, Eastern Cooperative Oncology Group performance status (ECOG PS), and Adult Comorbidity Evaluation-27 (ACE-27) comorbidity score.

RESULTS: One thousand four hundred eighty patients with lung cancer were included. There were no statistically significant differences in symptoms and QoL scores between age groups. Cough ( P = .006) and EQ-5D-5L mobility scores ( P = .006) were significantly worse for patients with an ECOG PS of 0-1. Dyspnea ( P = .035), hemoptysis ( P = .023), nausea ( P = .041), mobility ( P = .004), and self-care ( P = .0420) were significantly worse for those with higher ACE-27 scores (2-3 v 0-1). Palliative SACT was associated with a significant improvement in cough ( P < .001) and hemoptysis ( P = .025), but significantly negatively affected mobility ( P = .013). Patients receiving radical thoracic radiotherapy reported a significant improvement in hemoptysis ( P = .042) but worse pain ( P = .002) and fatigue ( P = .01). Other changes in symptom and QoL scores were not significant.

CONCLUSION: The symptoms and QoL reported at baseline and before and after both palliative SACT and radical thoracic radiotherapy are clinically relevant and meaningful. We have demonstrated that routine implementation of ePROMs into clinical practice is feasible and can inform clinical practice and future research.

Original languageEnglish
Pages (from-to)e2200150
JournalJCO Clinical Cancer Informatics
Issue number7
Early online date17 Apr 2023
Publication statusE-pub ahead of print - 17 Apr 2023


  • Adult
  • Humans
  • Quality of Life
  • Cough
  • Hemoptysis
  • Lung Neoplasms/diagnosis
  • Patient Reported Outcome Measures


Dive into the research topics of 'Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer'. Together they form a unique fingerprint.

Cite this